View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Analysis
December 10, 2021updated 11 Jul 2022 9:48am

Industrial automation innovation among pharmaceutical industry companies rebounded in the last quarter

Johnson & Johnson was the top industrial automation innovator in the pharmaceutical sector in the last quarter

By Michael Goodier

Research and innovation in industrial automation in the pharmaceutical sector has rebounded in the last quarter.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The most recent figures show that the number of industrial automation patent applications in the industry stood at 100 in the three months ending October – down from 114 over the same period last year.

Figures for patent grants related to industrial automation followed a different pattern to filings – stagnating from 65 in the three months ending October last year to 65 this year.

The figures are compiled by GlobalData, who track patent filings and grants from official offices around the world. Using textual analysis, as well as official patent classifications, these patents are grouped into key thematic areas, and linked to key companies across various industries.

Industrial automation is one of the key areas tracked by GlobalData. It has been identified as being a key disruptive force facing companies in the coming years, and is one of the areas that companies investing resources in now are expected to reap rewards from.

The figures also provide an insight into the largest innovators in the sector.

Johnson & Johnson was the top industrial automation innovator in the pharmaceutical sector in the last quarter. The company, which has its headquarters in the United States, filed 96 industrial automation related patents in the three months ending October. That was down from 117 over the same period last year.

It was followed by the United States based Thermo Fisher Scientific Inc with 51 industrial automation patent applications, Germany based Sartorius AG (21 applications), and Switzerland based F. Hoffmann-La Roche Ltd (18 applications).

Thermo Fisher Scientific Inc has recently ramped up R&D in industrial automation. It saw growth of 29.4% in related patent applications in the three months ending October compared to the same period last year - the highest percentage growth out of all companies tracked with more than 10 quarterly patents in the pharmaceutical sector.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology